APA (7th ed.) Citation

P, V., V, D. F., & R, A. (2024). Is the use of cetuximab in the first-line treatment of recurrent/metastatic head and neck cancer still important? Expert review of anticancer therapy, 24(7), 481. https://doi.org/10.1080/14737140.2024.2354772

Chicago Style (17th ed.) Citation

P, Vitale, De Falco V, and Addeo R. "Is the Use of Cetuximab in the First-line Treatment of Recurrent/metastatic Head and Neck Cancer Still Important?" Expert Review of Anticancer Therapy 24, no. 7 (2024): 481. https://doi.org/10.1080/14737140.2024.2354772.

MLA (9th ed.) Citation

P, Vitale, et al. "Is the Use of Cetuximab in the First-line Treatment of Recurrent/metastatic Head and Neck Cancer Still Important?" Expert Review of Anticancer Therapy, vol. 24, no. 7, 2024, p. 481, https://doi.org/10.1080/14737140.2024.2354772.